This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (16) Citing Articles via Google Scholar Google Scholar Articles by Daniels, L. B. Articles by Barrett-Connor, E. Search for Related Content PubMed PubMed Citation Articles by Daniels, L. B. Articles by Barrett-Connor, E. Related Collections Related Article

CLINICAL RESEARCH: CORONARY HEART DISEASE

Lipoprotein-Associated Phospholipase A2 Is an Independent Predictor of Incident Coronary Heart Disease in an Apparently Healthy Older Population

The Rancho Bernardo Study

Lori B. Daniels, MD^_*,_*, Gail A. Laughlin, PhD, Mark J. Sarno, BA, Ricki Bettencourt, MS, Robert L. Wolfert, PhD and Elizabeth Barrett-Connor, MD

^_* Division of Cardiology, Department of Medicine, University of California at San Diego, San Diego, California
Department of Family and Preventive Medicine, University of California at San Diego, La Jolla, California
diaDexus, Inc., South San Francisco, California.

Manuscript received June 27, 2007; revised manuscript received October 10, 2007, accepted October 11, 2007.

^_* Reprint requests and correspondence: Dr. Lori B. Daniels, Mail Code 0986, 9350 Campus Point Drive, Suite 1D, La Jolla, California 92037. (Email: lbdaniels{at}ucsd.edu).

Objectives: Lipoprotein-associated phospholipase A2 (Lp-PLA2) levels predict incident coronary heart disease (CHD) in adults without known CHD, independent of heart disease risk factors. We examined whether the independent association was apparent in older adults.

Background: Serum levels of Lp-PLA2, an enzyme that hydrolyzes oxidized phospholipids to yield potentially proatherogenic particles, have been associated with CHD and may help predict cardiovascular risk.

Methods: Participants were 1,077 community-dwelling men and women, median age 72 years, who had no known CHD at baseline (1984 to 1987) when blood samples and risk factor data were collected. Participants were followed for CHD events for a mean of 16 years, through 2002. Cox proportional hazards regression models were used to examine the association of serum Lp-PLA2 with incident CHD (myocardial infarction, angina, or coronary revascularization).

Results: The Lp-PLA2 levels positively correlated with age (r = 0.09), body mass index (r = 0.11), low-density lipoprotein (r = 0.37), triglycerides (r = 0.25), and C-reactive protein (r = 0.10), and negatively correlated with high-density lipoprotein (r = –0.27) (all p < 0.05). During follow-up, 228 participants had incident CHD events. Lipoprotein-associated phospholipase A2 levels in the second, third, and fourth quartiles predicted an increased risk of CHD compared with the lowest quartile (hazard ratios 1.66, 1.80, and 1.89, respectively; p < 0.05 for each). This association persisted after adjusting for C-reactive protein and other CHD risk factors.

Conclusions: Elevated Lp-PLA2 levels predict CHD events in apparently healthy older adults, independent of CHD risk factors.

Abbreviations and Acronyms   BMI = body mass index   CHD = coronary heart disease   CI = confidence interval   CRP = C-reactive protein   HDL = high-density lipoprotein   HR = hazard ratio   LDL = low-density lipoprotein   Lp-PLA2 = lipoprotein-associated phospholipase A2

Related Article

Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 51: A31-A32. [Full Text] [PDF]

This article has been cited by other articles:

				M. Madjid and J. T. Willerson Inflammatory markers in coronary heart disease Br. Med. Bull., December 1, 2011; 100(1): 23 - 38. [Abstract] [Full Text] [PDF]

				Writing Committee Members, P. Greenland, J. S. Alpert, G. A. Beller, E. J. Benjamin, M. J. Budoff, Z. A. Fayad, E. Foster, M. A. Hlatky, J. M. Hodgson, et al. 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation, December 21, 2010; 122(25): e584 - e636. [Full Text] [PDF]

				Writing Committee Members, P. Greenland, J. S. Alpert, G. A. Beller, E. J. Benjamin, M. J. Budoff, Z. A. Fayad, E. Foster, M. A. Hlatky, J. M. Hodgson, et al. 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation, December 21, 2010; 122(25): 2748 - 2764. [Full Text] [PDF]

				P. Greenland, J. S. Alpert, G. A. Beller, E. J. Benjamin, M. J. Budoff, Z. A. Fayad, E. Foster, M. A. Hlatky, J. M. Hodgson, F. G. Kushner, et al. 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance J. Am. Coll. Cardiol., December 14, 2010; 56(25): e50 - e103. [Full Text] [PDF]

				P. Greenland, J. S. Alpert, G. A. Beller, E. J. Benjamin, M. J. Budoff, Z. A. Fayad, E. Foster, M. A. Hlatky, J. M. Hodgson, F. G. Kushner, et al. 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance J. Am. Coll. Cardiol., December 14, 2010; 56(25): 2182 - 2199. [Full Text] [PDF]

				Z. Mallat, G. Lambeau, and A. Tedgui Lipoprotein-Associated and Secreted Phospholipases A2 in Cardiovascular Disease: Roles as Biological Effectors and Biomarkers Circulation, November 23, 2010; 122(21): 2183 - 2200. [Full Text] [PDF]

				K. P. Markakis, M. K. Koropouli, S. Grammenou-Savvoglou, E. C. van Winden, A. A. Dimitriou, C. A. Demopoulos, A. D. Tselepis, and E. E. Kotsifaki Implication of lipoprotein associated phospholipase A2 activity in oxLDL uptake by macrophages J. Lipid Res., August 1, 2010; 51(8): 2191 - 2201. [Abstract] [Full Text] [PDF]

				S. Tsimikas, J. Willeit, M. Knoflach, M. Mayr, G. Egger, M. Notdurfter, J. L. Witztum, C. J. Wiedermann, Q. Xu, and S. Kiechl Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study Eur. Heart J., January 1, 2009; 30(1): 107 - 115. [Abstract] [Full Text] [PDF]